Healthcare and Pharmaceutical Sector

The US Food and Drug Administration approved Revolution Medicines' oral therapy daraxonrasib under the brand name Rasonque for advanced pancreatic cancer, clearing the first targeted treatment for a malignancy with one of the highest mortality rates in medicine. In a late-stage clinical trial of 500 patients, those who took the daily pill achieved a median overall survival time of 13.2 months, compared to 6.7 months for patients treated with standard chemotherapy. The drug targets and shuts down mutations in the KRAS gene, which drives tumor growth in more than 90 percent of pancreatic tumors and has long resisted therapeutic intervention. Revolution Medicines priced the treatment at $39,800 for a 30-day supply in the US. The regulatory agency reviewed the drug under an expedited pathway that shortened evaluation timelines to roughly a month, granting clearance six months ahead of its official deadline. The speed of the approval triggers a commercial launch for a drug that analysts project could generate $11.5 billion in peak annual sales, while pushing Revolution Medicines stock up 166 percent this year. While the therapy nearly doubles survival, it carries severe side effects including skin toxicity, diarrhea, and fatigue, with roughly 44 percent of trial participants experiencing severe adverse events compared to 57.5 percent on chemotherapy.

Turkey's Competition Authority opened an antitrust investigation into Teva Pharmaceutical Industries for allegedly blocking generic rivals through patent system manipulation and misleading health authorities. Regulators are examining whether the company engaged in practices designed to make market entry more difficult for competitors, including divisional patent applications and spreading doubts about the safety and efficacy of rival products. The inquiry echoes a prior European Commission case where Teva was hit with a $503 million fine for delaying competition to its multiple sclerosis medicine Copaxone. Teva stated the Turkish matter relates to a legacy issue similar to the European case and that it denies any wrongdoing. Teva shares traded up 1.49% at 37.48 on the news.

The US Food and Drug Administration approved Mimrylo to treat adults with polycythemia vera. Developed by Takeda and Protagonist Therapeutics, the drug is the first approved treatment for the rare blood disorder that mimics hepcidin to regulate iron and limit red blood cell overproduction. Patients with the condition often require frequent phlebotomies to maintain hematocrit levels below 45 percent and reduce cardiovascular risks like blood clots and strokes. In the phase 3 VERIFY study of 293 adults requiring frequent phlebotomies despite standard care, 76.9 percent of patients receiving Mimrylo needed no phlebotomies between weeks 20 and 32 compared to 32.9 percent on placebo. The drug was administered subcutaneously once weekly starting at 19 mg and received priority review.

Moderna and Merck reported that their personalized melanoma vaccine intismeran met its goals in a Phase 3 trial of 1,137 patients when combined with Merck's Keytruda. The combination reduced the risk of cancer recurrence and spread compared with Keytruda alone. This marks the first positive late-stage trial result for an mRNA cancer vaccine. Moderna shares closed up 177% following the announcement. Meanwhile, BioNTech and Genentech terminated a Phase 2 trial of their own personalized mRNA cancer vaccine after an independent Data Safety Monitoring Board identified a numerical imbalance in overall survival.

Channelnewsasia.com reports that Huawei plans to expand its artificial intelligence partnerships with domestic pharmaceutical companies into drug development and clinical practice. William Zhang, president of Huawei's healthcare business unit, stated that the Chinese technology conglomerate aims to build on existing hospital clinical collaborations to cover areas from drug manufacturing to final implementation. Huawei provides tools for screening potential drug compounds alongside its Ascend and Kunpeng chips. In May, the company partnered with state-owned Guangzhou Pharmaceutical Holdings on an AI drug research model project. The push comes as rival U.S. chipmaker Nvidia pursues similar partnerships with drugmakers like Eli Lilly and Novo Nordisk to capture demand in AI-powered drug discovery.

Sword Health has agreed to acquire mental health company Headspace through a cash purchase of its parent company, OrangeDot. The transaction combines two digital health unicorns and is scheduled to become effective on September 14, following a material change filing submitted to the Massachusetts Health Policy Commission on July 22. Sword Health recently raised $40 million in 2025 at a valuation exceeding $4 billion, bringing its total funding to $493 million. The acquisition broadens Sword Health's platform beyond its core virtual physical therapy offering into mental health services. Financial terms of the transaction were not disclosed in the regulatory paperwork.

Boston Scientific suffered a cyberattack that triggered a global disruption across its operations, freezing order processing and product shipments. The medical technology company detected the security incident on Tuesday and disclosed it in a federal regulatory filing on Wednesday. Investigators and third-party cybersecurity experts have not yet established a timeline for fully restoring the affected network and business applications. The network outage forced thousands of staff at the company's Cork, Ireland campus to be sent home. Shares dropped more than 4% following the disclosure, adding fresh uncertainty to an already challenging year for the device maker.

SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.